• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Idecabtagene vicleucel showed a response in pre-treated multiple myeloma

bySze Wah Samuel ChanandHarsh Shah
February 26, 2021
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Idecabtagene vicleucel treatment showed substantial antitumor activity in the majority of pre-treated patients with refractory and relapsed myeloma.

2. Almost all patients had grade 3 or 4 adverse events, which included myelosuppression and cytokine release syndrome.

Evidence Rating Level: 2 (Good)

Study Rundown: Multiple myeloma patients who progressed on proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies have few treatment options. Additionally, the median progression-free survival for these patients is usually in the range of three to four months. As such, this trial evaluated the response and safety of a B-cell maturation antigen-directed CAR T cell, called idecabtagene vicleucel (ide-cel) in heavily pre-treated multiple myeloma patients. The majority of patients had a response to treatment, and progression-free survival (PFS) was 8.8 months. Nearly all patients experienced grade 3 or 4 adverse events primarily consisting of myelosuppression and cytokine release syndrome. The study was limited by the short-term follow-up period, thereby, the study was unable to determine the long-term effects of the treatment. Nonetheless, this study’s results are significant, and its findings highlight evidence of promising CAR-T cell therapy for the treatment of relapsed multiple myeloma.

Click here to read the study in the NEJM

Relevant Reading: Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

RELATED REPORTS

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma

#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma

CAR-T Cell Therapy for Relapsed or Refractory High-Risk Neuroblastoma

In-Depth [prospective cohort]: This phase 2 trial enrolled 140 patients. The study inclusion criteria were patients with relapsed and refractory multiple myeloma and the prior exposure to a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Patients that were below the age of 18 years of age were excluded from the trial. The primary outcome was the overall response to treatment – either a partial response or better. 128 patients received the ide-cel treatment, and the median follow-up was 13.3 months. Overall, 94 of 128 patients (73%) had a response, and 42 of 128 patients (33%) had complete responses or better. Minimal residual disease (MRD)-negative status was confirmed in 33 of the 128 patients (26%). Median PFS was 8.8 months (95% confidence interval, 5.6 to 11.6 months). Additionally, the safety profile of the treatment showed common toxic effects such as neutropenia (117 of 128 patients, 91%), anemia (107 of 128 patients, 84%), and thrombocytopenia (81 of 128 patients, 63%). Furthermore, cytokine release syndrome occurred in 84% of patients (107 of 128 patients), of which 5% of the total patients had grade 3 or higher adverse events. Overall, this study indicated the idecabtagene vicleucel treatment was effective for refractory multiple myeloma; however, most patients experienced serious adverse events.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CAR-T cell therapyidecabtagene vicleucelprogression-free survivalrelapsed and refractory multiple myeloma
Previous Post

#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia

Next Post

Xanomeline-trospium treatment showed improvement in patients with schizophrenia

RelatedReports

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma
StudyGraphics

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma

August 8, 2024
#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma
StudyGraphics

#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma

July 26, 2024
Quick Take: Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents A Voxelwise and Genome-Wide Association Study
Oncology

CAR-T Cell Therapy for Relapsed or Refractory High-Risk Neuroblastoma

April 17, 2023
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma
Chronic Disease

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

June 29, 2022
Next Post
Parents often unaware of adolescents’ suicidal thoughts

Xanomeline-trospium treatment showed improvement in patients with schizophrenia

Simvastatin associated with slowed fibroid growth in mice

Relugolix combination therapy led to reduction in uterine fibroid symptoms

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

2 Minute Medicine Rewind March 1, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Digital health apps may have limited role in reduction of migraine symptoms
  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.